These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
817 related articles for article (PubMed ID: 15947090)
1. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090 [TBL] [Abstract][Full Text] [Related]
2. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978 [TBL] [Abstract][Full Text] [Related]
3. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Miao L; Yang J; Huang C; Shen Z Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045 [TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031 [TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219 [TBL] [Abstract][Full Text] [Related]
7. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801 [TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326 [TBL] [Abstract][Full Text] [Related]
9. Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958 [TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919 [TBL] [Abstract][Full Text] [Related]
11. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Oner Ozgon G; Langaee TY; Feng H; Buyru N; Ulutin T; Hatemi AC; Siva A; Saip S; Johnson JA Eur J Clin Pharmacol; 2008 Sep; 64(9):889-94. PubMed ID: 18542936 [TBL] [Abstract][Full Text] [Related]
12. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959 [TBL] [Abstract][Full Text] [Related]
13. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Linder MW; Bon Homme M; Reynolds KK; Gage BF; Eby C; Silvestrov N; Valdes R Clin Chem; 2009 Oct; 55(10):1861-8. PubMed ID: 19679631 [TBL] [Abstract][Full Text] [Related]
14. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. Choi JR; Kim JO; Kang DR; Yoon SA; Shin JY; Zhang X; Roh MO; Hong HJ; Wang YP; Jo KH; Lee KS; Yun HJ; Oh YS; Yoo KD; Jeon HG; Lee YS; Kang TS; Park HJ; Chung MW; Kang JH J Hum Genet; 2011 Apr; 56(4):290-5. PubMed ID: 21326313 [TBL] [Abstract][Full Text] [Related]
15. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797 [TBL] [Abstract][Full Text] [Related]
16. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898 [TBL] [Abstract][Full Text] [Related]
17. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen. El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669 [TBL] [Abstract][Full Text] [Related]
18. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements]. Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951 [TBL] [Abstract][Full Text] [Related]
19. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348 [TBL] [Abstract][Full Text] [Related]
20. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism. Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]